On April 5, 2024 NiKang Therapeutics Inc. ("NiKang"), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, reported the unveiling of NKT3447 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 (Press release, NiKang Therapeutics, APR 5, 2024, View Source [SID1234641830]). NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action. It downregulates cyclin E and suppresses activating phosphorylation of CDK2 on Thr160.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to share the discovery of NKT3447, a highly selective CDK2 inhibitor with unique properties, at the AACR (Free AACR Whitepaper) Annual Meeting", said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang. "This is the first of three programs targeting the cell cycle that we are expecting to bring to clinic. We have strong conviction in CDK2 as an oncology target and have built an industry-leading potential best in class and/or first in class portfolio that also includes a CDK2-selective degrader and a CDK2/4 dual degrader. Despite clinical success with drugs targeting the cell cycle, it has been challenging to identify inhibitors of CDK2 which have sufficient selectivity against CDK1, and which do not cause a compensatory increase of cyclin E. We have developed a platform to bring unique and selective drugs targeting CDK2 which address these challenges to clinic. We appreciate the opportunity to share the unique properties of NKT3447 and are enthusiastic about exploring the potential of NKT3447 in treating various cancers driven by CDK2 and cyclin E."
NiKang has initiated a phase 1/1b, open-label, dose escalation and expansion study of NKT3447 as a single agent. This first-in-human study (NCT06264921) is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of NKT3447, administered orally, in adult patients with advanced or metastatic solid tumors.
Poster Presentation Details:
Title:
Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing CDK2, downregulating cyclin E, and achieving prolonged pathway inhibition
Presenter:
Ke Liu, Ph.D.
Abstract Number:
5705/5 (link to abstract)
Session:
Pharmacologic Targeting of Cell Cycle Proteins
Date/Time:
1:30 – 5:00pm PT on April 9, 2024